Infex scientists achieve breakthrough to overcome critical priority drug resistant infections

Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…


Infex agrees partnership with Colibri Scientific to provide services for RESP-X program

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…


Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

Alderley Park, Cheshire –  One of the UK’s leading infectious disease biotech…


Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics

Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr…


Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership

Alderley Park, Cheshire - Infex Therapeutics is pressing ahead with a major…


Tackling underlying respiratory conditions for this pandemic and next

During the COVID-19 pandemic, one of the many phrases that has become…


Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…


Infex appoints Lonza to manufacture new lung infection drug

Alderley Park, Cheshire Infex Therapeutics has awarded a £1m contract to Lonza…


Deals agreed as Infex’s resistance bypass drug program heads for clinic

Alderley Park, Cheshire Infex Therapeutics has appointed Pharmaron to help…


Infex focuses on pandemic preparedness with Covid patent

Infex Therapeutics has filed for a UK patent for a novel therapy designed to…